OncoSpherix News & Events
OncoSpherix Presents at Biopharma Drug Discovery Nexus East Coast 2023 in Philadelphia on Wednesday, October 18 at 9:45 AM.
October 16, 2023 Atlanta, GA – October 16, 2023 – The CEO of OncoSpherix, Inc, Dr. Margaret K. Offermann, MD, PhD, is delivering a keynote address at Biopharma Drug Discovery Nexus East Coast 2023 in Philadelphia on Wednesday, October 18 at 9:45 AM. Her presentation...
OncoSpherix expands leadership team with the appointment of Allan Valmonte, M.B.A., as Vice President of Business Operations
April 28, 2023 Allan Valmonte, M.B.A., former Executive Director, Program Management Office (PMO) at Taysha Gene Therapies, joins OncoSpherix with over 25 years of program/portfolio management and clinical operations experience in the biotechnology and pharmaceutical...
OncoSpherix expands leadership team with the appointment of Steve Coats, Ph.D. as Vice President of Chemistry
April 28, 2023 Dr. Steve Coats, former Senior Director of Chemistry at Cocrystal Pharma, joins OncoSpherix with over 25 years of drug discovery and development experience in biotechnology and large pharmaceutical companies. Atlanta, GA – April 28, 2023 – OncoSpherix,...
OncoSpherix to Present Data from its Hypoxia Inducible Factor (HIF) Inhibitor 64B in Uveal Melanoma
April 12, 2023 64B is a small molecule therapeutic that inhibits the function of hypoxia inducible factors (HIFs) 64B given systemically inhibits primary tumor growth and metastases 64B was far superior to either sunitinib or selumetinib at causing a regression in...
OncoSpherix CEO to Serve as Keynote Speaker at 5th Meridian Drug Discovery Conference in Boston on Tuesday, November 8, 2022
The 5th Meridian Drug Discovery Conference will be held at the Embassy Suites by Hilton at Boston Longan Airport on November 7-8, 2022. Dr. Margaret Offermann will present a keynote address entitled "Mechanism Matters: Overcoming Past Failures in Developing HIF...
OncoSpherix’s CEO Will Give Keynote Presentation Entitled “Overcoming Past Challenges in Developing Safe and Effective Small Molecule Hypoxia Inducible Factor (HIF) Inhibitors for Treatment Of Aggressive Cancers” in San Francisco on Thursday, October 27
The Agile Falcon Drug Discovery Strategic Summit will be held at the Grand Hyatt at the San Francisco Airport on October 27-28, 2022. OncoSpherix's CEO, Dr. Margaret Offermann, will be presenting a keynote address entitled "Overcoming Past Challenges in Developing...
OncoSpherix’s CEO is Keynote Speaker and Moderator at Global Women in STEM Leadership Summit In Atlanta on June 6-7, 2022
The Global Women in STEM Leadership Summit is designed to inspire attendees through sessions tailored specifically for promoting women in STEM. It brings together influential leaders and founders from industry, academia, nonprofit and government to share their...
Serial Entrepreneur and Biotech Leader Thomas Saylor Joins Business Advisory Board of OncoSpherix
OncoSpherix is pleased to announce that Thomas Saylor has joined the company’s business advisory board. Mr. Saylor has served as CEO of six emerging biotech companies in the U.S., Europe and Asia, leading enterprises that cover drug development, pharmaceutical...
Internationally Renowned Medical Oncologist Dr. Harvey Golomb Joins Clinical Advisory Board of OncoSpherix
OncoSpherix is pleased to announce that Dr. Harvey Golomb has joined the Clinical Advisory Board of OncoSpherix. Dr. Golomb’s recognition as a preeminent leader in oncology began early in his career, as reflected by his election in 1990 as President of the American...
OncoSpherix’s Chief Scientific Officer Dr. Erwin Van Meir Honored with Endowed Professorship for Brain Cancer Research
Dr. Erwin Van Meir is the inaugural David Hart White Endowed Professorship for Brain Cancer Research at the National Cancer Institute-designated O’Neal Comprehensive Cancer Center at the University of Alabama Birmingham. Dr. Van Meir’s research illuminates how genetic...